Biophytis SA (6XB3) AI Stock Analysis

1 Followers

Biophytis SA

(Frankfurt:6XB3)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Focused clinical-stage specializationSpecialization in age-related diseases and muscle-function therapeutics indicates a focused R&D strategy and domain expertise. A concentrated pipeline can create differentiated assets, streamline trial design and partner appeal, supporting durable value creation if clinical progress continues.

Negative Factors

No revenue over multiple yearsAbsence of product revenue across multiple years means the company lacks operating cash generation and remains fully reliant on financing or partners. This structural revenue gap increases execution risk and constrains long-term sustainability until commercialization or licensing occurs.

Biophytis SA (6XB3) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 16.02M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.0
Beta (1Y): 72.09
Revenue Growth: ―
EPS Growth: 90.97%
Country: Germany
Employees: 20
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Biophytis SA Business Overview & Revenue Model

Company Description

Biophytis S.A. is a clinical-stage biotechnology company dedicated to creating therapies designed to mitigate age-related degenerative processes and enhance functional well-being for patients. The company's scientific approach centers on identifying...

Biophytis SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:6XB3 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:AELIS	47Neutral	EUR 11.99M	-2.65	―	―	-97.09%	45.00%
FR:POXEL	46Neutral	EUR 8.22M	-0.39	33.88%	―	―	―
FR:ABVX	44Neutral	EUR 7.29B	-17.52	-85.88%	―	―	―
FR:ALVAL	43Neutral	EUR 21.85M	-2.09	-84.11%	―	183.47%	57.15%
FR:ALNEV	37Underperform	EUR 140.09K	0.00	-26.52%	―	-9.52%	100.00%

* Healthcare Sector Average

Performance Comparison

DE:6XB3 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:6XB3	Biophytis SA	0.02	-0.04	-67.69%
FR:ABVX	Abivax SA	79.10	-18.10	-18.62%
FR:POXEL	Poxel SA	0.14	-0.12	-44.87%
FR:ALVAL	Valbiotis SA	0.60	0.03	4.35%
FR:ALNEV	Neovacs SA	0.07	-248.93	-99.97%
FR:AELIS	Aelis Farma SA	0.92	-0.17	-15.60%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Biophytis SA AI Stock Analysis